Eli Lilly unveiled its newest manufacturing facility in Concord, N.C., Friday. The facility will help alleviate GLP-1 shortages.
Gilead stock jumped Friday after surprising Wall Street with preclinical test results for an under-the-radar weight-loss drug.
If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.